Significant Pharmacokinetic and Pharmacodynamic Interaction of Warfarin With the NO-Independent sGC Activator HMR1766

HMR1766 is a new nitric oxide (NO)–independent activator of soluble guanylyl cyclase (sGC) in development for the treatment of cardiovascular diseases and chronic heart failure. A significant fraction of patients to be treated with HMR1766 is expected to be maintained on warfarin. Because HMR1766 is...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical pharmacology 2007-01, Vol.47 (1), p.70-77
Hauptverfasser:	Oberwittler, Heike, Hirschfeld-Warneken, Andreas, Wesch, Roland, Willerich, Hans, Teichert, Lenore, Lehr, Karl-Heinz, Ding, Reinhard, Haefeli, Walter Emil, Mikus, Gerd
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Analysis of Variance Anticoagulants - administration & dosage Anticoagulants - blood Anticoagulants - metabolism Anticoagulants - pharmacokinetics Area Under Curve Aryl Hydrocarbon Hydroxylases - metabolism Chromatography, High Pressure Liquid Cross-Over Studies CYP2C9 polymorphism Cytochrome P-450 CYP2C9 Dosage and administration Double-Blind Method Drug interaction Drug interactions Guanylate Cyclase - metabolism Health aspects HMR1766 Humans Male Nephelometry and Turbidimetry Nitric oxide NO-independent soluble guanylyl cyclase activator ortho-Aminobenzoates - blood ortho-Aminobenzoates - metabolism Pharmacokinetics Pharmacology Prothrombin Time Sulfonamides - blood Sulfonamides - metabolism Tablets Time Factors Warfarin Warfarin - administration & dosage Warfarin - blood Warfarin - metabolism Warfarin - pharmacokinetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!